| Schedule of Earnings Per Share, Basic and Diluted |
The following table sets forth the computation of the basic and diluted net income (loss) per share attributable to common stockholders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended July 31, | | Six months ended July 31, | | (in thousands, except share and per share data) | | 2025 | | 2024 | | 2025 | | 2024 | | Basic net income (loss) per share: | | | | | | | | | | Numerator: | | | | | | | | | | Net income (loss) attributable to common stockholders | | $ | 26,751 | | | $ | (4,057) | | | $ | 27,521 | | | $ | (7,874) | | | Denominator: | | | | | | | | | | Weighted-average common shares outstanding, basic | | 122,854,629 | | 126,535,481 | | 124,229,932 | | 125,967,631 | | Net income (loss) per share: | | | | | | | | | | Net income (loss) per share attributable to common stockholders, basic | | $ | 0.22 | | | $ | (0.03) | | | $ | 0.22 | | | $ | (0.06) | | | | | | | | | | | | Diluted net income (loss) per share: | | | | | | | | | | Numerator: | | | | | | | | | | Net income (loss) | | $ | 26,751 | | | $ | (4,057) | | | $ | 27,521 | | | $ | (7,874) | | | Fair value adjustment related to contingent consideration | | (23,400) | | | — | | | (21,600) | | | — | | | Net income (loss), diluted | | $ | 3,351 | | | $ | (4,057) | | | $ | 5,921 | | | $ | (7,874) | | | Denominator: | | | | | | | | | | Number of shares used in basic calculation | | 122,854,629 | | 126,535,481 | | 124,229,932 | | 125,967,631 | | Dilutive effect of employee share-based awards | | 5,380,873 | | | — | | | 4,810,421 | | | — | | | Dilutive effect of incentive pool | | 1,129,194 | | | — | | | 1,254,875 | | | — | | | Dilutive effect of earnout arrangement | | 1,436,112 | | | — | | | 718,056 | | | — | | | Weighted-average common shares outstanding, diluted | | 130,800,808 | | 126,535,481 | | 131,013,284 | | 125,967,631 | | Net income (loss) per share attributable to common stockholders, diluted | | $ | 0.03 | | | $ | (0.03) | | | $ | 0.05 | | | $ | (0.06) | |
|
| Schedule of Antidilutive Securities |
Anti-dilutive common equivalent shares were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended July 31, | | Six months ended July 31, | | | 2025 | | 2024 | | 2025 | | 2024 | | Options to purchase common stock | | 181,750 | | | 1,753,179 | | | 507,946 | | | 1,753,179 | | | Restricted stock and restricted stock units | | 3,400,013 | | | 10,833,317 | | | 2,818,227 | | | 10,833,317 | | | Shares estimated to be purchased under ESPP | | — | | | 373,424 | | | — | | | 373,424 | | | Performance-based restricted stock units | | 2,995,000 | | | 3,530,000 | | | 2,862,500 | | | 3,530,000 | | | | | | | | | | | | Total anti-dilutive common equivalent shares | | 6,576,763 | | | 16,489,920 | | | 6,188,673 | | | 16,489,920 | |
|